GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Change In Receivables : ₦1,332 Mil (TTM As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Change In Receivables?

GlaxoSmithKline Consumer Nigeria's change in receivables for the quarter that ended in Jun. 2023 was ₦0 Mil. It means GlaxoSmithKline Consumer Nigeria's Accounts Receivable stayed the same from Dec. 2022 to Jun. 2023 .

GlaxoSmithKline Consumer Nigeria's change in receivables for the fiscal year that ended in Dec. 2022 was ₦1,332 Mil. It means GlaxoSmithKline Consumer Nigeria's Accounts Receivable declined by ₦1,332 Mil from Dec. 2021 to Dec. 2022 .

GlaxoSmithKline Consumer Nigeria's Accounts Receivable for the quarter that ended in Jun. 2023 was ₦2,997 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. GlaxoSmithKline Consumer Nigeria's Days Sales Outstanding for the three months ended in Jun. 2023 was 73.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. GlaxoSmithKline Consumer Nigeria's liquidation value for the three months ended in Jun. 2023 was ₦3,489 Mil.

GlaxoSmithKline Consumer Nigeria Change In Receivables Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Change In Receivables Chart

GlaxoSmithKline Consumer Nigeria Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

1,149.05

-1,104.53

2,030.46

-520.93

1,332.28

GlaxoSmithKline Consumer Nigeria Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															-589.40	-521.62	1,689.00	754.30	-

GlaxoSmithKline Consumer Nigeria Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₦1,332 Mil.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

GlaxoSmithKline Consumer Nigeria's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2997.004	/	3731.801	*	91
=	73.28

2. In Ben Graham's calculation of liquidation value, GlaxoSmithKline Consumer Nigeria's accounts receivable are only considered to be worth 75% of book value:

GlaxoSmithKline Consumer Nigeria's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	21203.332	-	21053.574	+	0.75 * 2997.004	+	0.5 * 2182.243
=	3,489

GlaxoSmithKline Consumer Nigeria Change In Receivables Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA

Website

https://www.ng.gsk.com

GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines